Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5520
Name head and neck squamous cell carcinoma
Definition A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma head and neck squamous cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA act mut Gedatolisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA E545K Rigosertib Sodium head and neck squamous cell carcinoma sensitive detail...
TP53 mutant AZD7762 + Cisplatin head and neck squamous cell carcinoma sensitive detail...
FGFR1 over exp Infigratinib head and neck squamous cell carcinoma sensitive detail...
FBXW7 R505C Vorinostat head and neck squamous cell carcinoma sensitive detail...
PIK3CA mutant Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA amp Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
PTEN mutant Taselisib head and neck squamous cell carcinoma resistant detail...
FGFR3 over exp Rogaratinib head and neck squamous cell carcinoma sensitive detail...
HRAS Q61L Sirolimus + Trametinib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Sirolimus + Trametinib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
PTEN del Taselisib head and neck squamous cell carcinoma resistant detail...
PIK3CA E542K GDC-0980 head and neck squamous cell carcinoma sensitive detail...
PIK3CA over exp Gedatolisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Gedatolisib head and neck squamous cell carcinoma sensitive detail...
CHEK1 positive CCT244747 + Radiotherapy head and neck squamous cell carcinoma sensitive detail...
CHEK1 positive CCT244747 + Paclitaxel + Radiotherapy head and neck squamous cell carcinoma sensitive detail...
FGFR3 D788N Infigratinib head and neck squamous cell carcinoma no benefit detail...
FGFR3 S131L Infigratinib head and neck squamous cell carcinoma decreased response detail...
FGFR1 positive AZD4547 + Vistusertib head and neck squamous cell carcinoma sensitive detail...
PTEN loss Rigosertib Sodium head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA amp AZD8055 head and neck squamous cell carcinoma predicted - sensitive detail...
PTEN loss AZD8055 head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA amp Dactolisib head and neck squamous cell carcinoma sensitive detail...
PTEN loss Dactolisib head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA act mut AZD8055 + Cetuximab head and neck squamous cell carcinoma predicted - sensitive detail...
FGFR3 positive Rogaratinib head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA E545K Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma predicted - sensitive detail...
PTEN R130Q Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma predicted - sensitive detail...
FGFR2 P253R Pazopanib head and neck squamous cell carcinoma predicted - sensitive detail...
TP53 mutant Buparlisib + Paclitaxel head and neck squamous cell carcinoma predicted - sensitive detail...
FGFR3 D764H Infigratinib head and neck squamous cell carcinoma no benefit detail...
PIK3CA wild-type PTEN pos Cetuximab + Cisplatin head and neck squamous cell carcinoma predicted - sensitive detail...
PTEN positive Cetuximab head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047R SHR-A1307 head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047R Cetuximab head and neck squamous cell carcinoma resistant detail...
PIK3CA amp Rigosertib Sodium head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS mutant Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA M1043V Celecoxib head and neck squamous cell carcinoma sensitive detail...
PIK3CA E542K Alpelisib + Cetuximab + Radiotherapy head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047R Sulindac head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA M1043V Sulindac head and neck squamous cell carcinoma sensitive detail...
PIK3CA R38C Sulindac head and neck squamous cell carcinoma sensitive detail...
PIK3CA E542K PIK3CA F744L Sulindac head and neck squamous cell carcinoma sensitive detail...
HRAS over exp Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Alpelisib + Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Tipifarnib + Uprosertib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Sapanisertib + Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA F977Y Pictilisib head and neck squamous cell carcinoma resistant detail...
SMARCB1 inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
SMARCA4 inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
PBRM1 inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
ARID1B inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
ARID2 inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
HRAS Q61L Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS G12C Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS A146T Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS G12S Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS G13R Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS K117N Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
CDKN2A del unspecified immune checkpoint inhibitor head and neck squamous cell carcinoma not predictive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00573989 Phase Ib/II Erlotinib + Pemetrexed Disodium Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer Terminated USA 0
NCT00588770 Phase III Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting USA 2
NCT00660218 Phase Ib/II Cetuximab + Paclitaxel A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer Unknown status USA 0
NCT00904345 Phase II Cetuximab Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) Terminated USA 0
NCT00956007 Phase III Cetuximab Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting USA | CAN 2
NCT00957853 Phase II Cetuximab Cixutumumab Preoperative Treatment With Cetuximab and/or IMC-A12 Completed USA 0
NCT01064479 Phase II Erlotinib Carboplatin Docetaxel Cisplatin Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck Completed USA 0
NCT01104922 Phase II Cetuximab Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 0
NCT01111058 Phase II Everolimus Everolimus Versus Placebo in Head and Neck Cancer Terminated USA 0
NCT01116336 Phase I Erlotinib Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck Completed USA 0
NCT01133678 Phase II Cetuximab + Cisplatin + Paclitaxel Everolimus Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Terminated USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA 4
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed USA 0
NCT01345669 Phase III Afatinib LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Terminated USA | CAN 27
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting USA 2
NCT01412229 Phase II Carboplatin + Cetuximab + Nab-paclitaxel Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed USA 0
NCT01437449 Phase II Cetuximab + Cisplatin + Docetaxel Carboplatin Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed USA 0
NCT01467115 Phase II Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER Completed USA 0
NCT01468896 Phase Ib/II Cetuximab Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01488318 Phase II Cetuximab + Dasatinib Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Terminated USA 0
NCT01577173 Phase II Cetuximab Duligotuzumab A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck Completed USA 10
NCT01581970 Phase II Cetuximab + Cyclophosphamide Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Completed USA 0
NCT01602315 Phase Ib/II Alpelisib + Cetuximab A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Terminated USA | CAN 7
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01612351 Phase II Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Active, not recruiting USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting USA 0
NCT01711541 Phase Ib/II Carboplatin + Etoposide + Veliparib Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Paclitaxel Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Active, not recruiting USA 0
NCT01711658 Phase II Cisplatin + Lapatinib + Radiotherapy Cisplatin + Radiotherapy TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. (TRYHARD) Active, not recruiting USA | CAN 0
NCT01716416 Phase I Cetuximab + Pazopanib Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) Completed USA 0
NCT01737008 Phase I Cisplatin Dacomitinib Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Completed CAN 0
NCT01744340 Phase Ib/II Eribulin Cetuximab A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Completed USA 0
NCT01783587 Phase I Afatinib Docetaxel Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Completed USA 0
NCT01794845 Phase II Cetuximab + Docetaxel Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma Terminated USA 0
NCT01810913 Phase II Docetaxel Cisplatin Cetuximab + Docetaxel Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Recruiting USA | CAN 1
NCT01816984 Phase Ib/II Cetuximab Buparlisib PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed USA 0
NCT01824823 Phase II Afatinib Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence Terminated USA 0
NCT01836029 Phase II Cisplatin Cetuximab + Fluorouracil Carboplatin Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA 0
NCT01852292 Phase II Buparlisib + Paclitaxel Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Terminated USA | CAN 16
NCT01871311 Phase I Cetuximab + Nilotinib A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab Terminated USA 0
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | CAN 3
NCT01935921 Phase I Cetuximab + Ipilimumab Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Active, not recruiting USA 0
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA 2
NCT01979211 Phase II Cetuximab Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 0
NCT02035527 Phase Ib/II Cisplatin + Docetaxel + Sorafenib Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA 0
NCT02057107 Phase II Cetuximab Docetaxel Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) Recruiting USA 0
NCT02083692 Phase I Metformin Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Completed USA 0
NCT02101034 Phase Ib/II Cetuximab + Palbociclib PD 0332991 and Cetuximab in Patients With Incurable SCCHN Active, not recruiting USA 0
NCT02105636 Phase III Methotrexate Cetuximab Docetaxel Nivolumab Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Unknown status USA | CAN 13
NCT02110082 Phase I Cetuximab + Urelumab Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Completed USA 0
NCT02124707 Phase II Carboplatin + Cetuximab + Paclitaxel Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN Completed USA 0
NCT02124850 Phase I Cetuximab A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 Terminated USA 0
NCT02128906 Phase II Cetuximab + Docetaxel Cisplatin Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC Recruiting USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 1
NCT02178072 Phase II Azacitidine Window Trial 5-aza in HNSCC, T-tare Recruiting USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02196168 Phase II Adavosertib Cisplatin Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated CAN 0
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated USA | CAN 5
NCT02207530 Phase II Durvalumab Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. Completed USA | CAN 12
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed USA 0
NCT02252042 Phase III Pembrolizumab Methotrexate Cetuximab Docetaxel Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Active, not recruiting 0
NCT02255097 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Completed 0
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed USA | CAN 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA 3
NCT02270814 Phase II Carboplatin + Cetuximab + Nab-paclitaxel Cetuximab + Cisplatin + Nab-paclitaxel Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02277184 Phase I Cisplatin + Ficlatuzumab Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Terminated USA 0
NCT02277197 Phase I Cetuximab + Ficlatuzumab Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed USA 0
NCT02282371 Phase I Alpelisib + Cetuximab Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) Active, not recruiting USA 0
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Recruiting USA 0
NCT02291055 Phase Ib/II Durvalumab ADXS11-001 Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer Active, not recruiting USA 0
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA 3
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated USA 0
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Completed USA | CAN 13
NCT02325401 Phase I Cisplatin + Metformin Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA 1
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated USA 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Active, not recruiting 0
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA 1
NCT02369874 Phase III Durvalumab + Tremelimumab Durvalumab Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Completed USA 23
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed USA 5
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed USA 0
NCT02381535 Phase I Cisplatin Onalespib Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting USA | CAN 0
NCT02383927 Phase II Tipifarnib Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Completed USA 9
NCT02402348 Phase I Metformin Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis Terminated USA 0
NCT02415881 Phase I Panitumumab Phase I Panitumumab IRDye800 Optical Imaging Study Completed USA 0
NCT02422979 Phase I ASP-1929 Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer Completed USA 0
NCT02423863 Phase II Poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Completed USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated USA 1
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02473731 Phase I CDX-3379 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Completed USA 0
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Completed USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02499120 Phase II Palbociclib Cetuximab Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer Unknown status USA 14
NCT02499328 Phase Ib/II AZD9150 + Durvalumab AZD5069 + Durvalumab Durvalumab AZD9150 Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Active, not recruiting USA 5
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting USA 2
NCT02508246 Phase I Adavosertib Docetaxel Cisplatin AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck Completed USA 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | CAN 2
NCT02537223 Phase I Alpelisib Cisplatin Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer Completed CAN 0
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA 1
NCT02551159 Phase III Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Completed USA | CAN 21
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Active, not recruiting USA | CAN 6
NCT02555644 Phase I Prexasertib Cisplatin Cetuximab A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer Completed USA 1
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02567422 Phase I Berzosertib + Cisplatin VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT02573493 Phase II Cisplatin + Nab-paclitaxel Cetuximab + Nab-paclitaxel Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Active, not recruiting USA 0
NCT02585973 Phase I Adavosertib + Cisplatin Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Completed USA 0
NCT02586207 Phase I Cisplatin + Pembrolizumab Pembrolizumab in Combination With CRT for LA-SCCHN Active, not recruiting USA 0
NCT02609503 Phase II Pembrolizumab Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin Active, not recruiting USA 0
NCT02626000 Phase Ib/II Pembrolizumab + Talimogene laherparepvec Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA | CAN 9
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN 1
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn 0
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Active, not recruiting USA 0
NCT02641093 Phase II Cisplatin Pembrolizumab Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Active, not recruiting USA 0
NCT02643550 Phase Ib/II Cetuximab + Monalizumab Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 1
NCT02644122 Phase II SF1126 SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Terminated USA 0
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting USA 0
NCT02649530 Phase II LGK974 An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma Withdrawn USA 0
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed 2
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed USA | CAN 5
NCT02684253 Phase II Nivolumab Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed USA 0
NCT02706691 Phase II Infigratinib Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer Terminated USA 0
NCT02734537 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting USA 0
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 17
NCT02762513 Phase II Axitinib Expansion Trial for Axitinib In Head And Neck Cancer Completed USA 0
NCT02764593 Phase I Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Recruiting USA 0
NCT02775812 Phase I Cisplatin + Pembrolizumab Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02777385 Phase II Cisplatin + Pembrolizumab Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Recruiting USA 0
NCT02812524 Phase I Ipilimumab Ipilimumab for Head and Neck Cancer Patients Recruiting USA 0
NCT02823574 Phase II Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA | CAN 19
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting USA 0
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated USA 3
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed USA 0
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Active, not recruiting USA 0
NCT02949700 Phase Ib/II Cisplatin + Metformin Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02952586 Phase III Cisplatin Avelumab + Cisplatin Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Terminated USA | CAN 20
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02979977 Phase II Afatinib + Cetuximab Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck Recruiting USA 0
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Completed USA | CAN 1
NCT02990468 Phase I BMX-001 + Cisplatin A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN) Active, not recruiting USA 0
NCT02994069 Phase II Cisplatin Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers Recruiting USA 0
NCT03019003 Phase Ib/II Azacitidine + Durvalumab + Tremelimumab A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients Recruiting USA 0
NCT03022409 Phase I Olaparib Ceralasertib A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Completed USA 2
NCT03049618 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Recruiting USA 0
NCT03057613 Phase II Pembrolizumab A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck Completed USA 0
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting USA 0
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA 5
NCT03076281 Phase II Doxycycline Doxycycline + Metformin Metformin Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Active, not recruiting USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03082534 Phase II Cetuximab + Pembrolizumab Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03083873 Phase II LN-145 Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck Active, not recruiting USA 0
NCT03085719 Phase II Pembrolizumab Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN Recruiting USA 0
NCT03088059 Phase II Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil Biomarker-based Study in R/M SCCHN (UPSTREAM) Recruiting 4
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Unknown status USA 0
NCT03109158 Phase Ib/II Cetuximab + Fluorouracil + NC-6004 NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA 3
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Active, not recruiting USA 3
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03138070 Phase I Alpelisib A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 Unknown status CAN 0
NCT03138889 Phase I NKTR-214 + Pembrolizumab A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL) Recruiting USA 5
NCT03153982 Phase II Ruxolitinib Ruxolitinib in Operable Head and Neck Cancer Recruiting USA 0
NCT03162224 Phase Ib/II Durvalumab + MEDI0457 Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer Completed USA 0
NCT03162731 Phase I Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Active, not recruiting USA 0
NCT03174275 Phase II Carboplatin + Cisplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03194373 Phase II Carboplatin + Palbociclib Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting 9
NCT03212469 Phase Ib/II Durvalumab + Tremelimumab A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) Recruiting 1
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Completed USA 2
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting USA 0
NCT03238638 Phase II Epacadostat + Pembrolizumab A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Withdrawn USA 0
NCT03245489 Phase I Pembrolizumab Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting USA 0
NCT03246685 Phase II Pembrolizumab + PGG beta-glucan Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD Terminated USA 0
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting USA 1
NCT03247712 Phase Ib/II Nivolumab Neoadjuvant Immunoradiotherapy in Head & Neck Cancer Active, not recruiting USA 0
NCT03254927 Phase II CDX-3379 + Cetuximab A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT03258554 Phase II Cetuximab Durvalumab Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Suspended USA | CAN 0
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Completed USA 5
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Active, not recruiting USA 0
NCT03283605 Phase Ib/II Durvalumab + Tremelimumab Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas Recruiting CAN 0
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting USA | CAN 6
NCT03301896 Phase I LHC165 + Spartalizumab LHC165 Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting USA 6
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting USA | CAN 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Recruiting USA 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03325465 Phase II Epacadostat + Pembrolizumab Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck Withdrawn USA 0
NCT03336606 Phase I Tavolimab Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma Active, not recruiting USA 0
NCT03341936 Phase II Lirilumab + Nivolumab Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 0
NCT03342352 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Withdrawn 0
NCT03342911 Phase II Carboplatin + Nivolumab + Paclitaxel Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Suspended USA 0
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated USA 5
NCT03349710 Phase III Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed USA 9
NCT03356223 Phase II Abemaciclib Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) Recruiting 1
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting CAN 0
NCT03358472 Phase III Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting USA | CAN 12
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03370276 Phase Ib/II Cetuximab + Nivolumab Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03381183 Phase Ib/II Cyclophosphamide + Durvalumab + Tremelimumab IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03386838 Phase III BMS-986205 + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Withdrawn USA 0
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Active, not recruiting USA 0
NCT03406247 Phase II Ipilimumab + Nivolumab Nivolumab Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) Not yet recruiting 1
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting USA 1
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting USA 0
NCT03422536 Phase II Ficlatuzumab Cetuximab + Ficlatuzumab Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03447314 Phase I GSK1795091 + GSK3174998 GSK3174998 Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors Active, not recruiting USA | CAN 2
NCT03452137 Phase III Atezolizumab A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting USA | CAN 21
NCT03463161 Phase II Epacadostat + Pembrolizumab Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA) Terminated USA 0
NCT03468218 Phase II Cabozantinib + Pembrolizumab Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy Recruiting USA 0
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting USA 0
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting USA | CAN 5
NCT03498378 Phase I Avelumab + Cetuximab + Palbociclib Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Active, not recruiting USA 4
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03518606 Phase Ib/II Durvalumab + Tremelimumab + Vinorelbine Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) Active, not recruiting 1
NCT03521570 Phase II Nivolumab Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Recruiting USA 0
NCT03522584 Phase Ib/II Durvalumab + Tremelimumab Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT03529422 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Active, not recruiting USA 0
NCT03544723 Phase II Nivolumab Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Ad-p53 in Head and Neck Cancer Recruiting USA 0
NCT03546582 Phase II Pembrolizumab SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) Recruiting USA | CAN 0
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting USA | CAN 7
NCT03565783 Phase II Cemiplimab Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting USA 0
NCT03576417 Phase III Cisplatin Cisplatin + Nivolumab A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) Recruiting 1
NCT03589339 Phase I NBTXR3 NBTXR3 + unspecified PD-1 antibody NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03618654 Phase I Durvalumab + Metformin Durvalumab Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03624231 Phase II Durvalumab Durvalumab + Tremelimumab Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) Recruiting 1
NCT03625323 Phase II Eftilagimod alpha + Pembrolizumab Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) Recruiting USA 5
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting USA 1
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA 1
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Active, not recruiting USA 0
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Active, not recruiting USA | CAN 8
NCT03645928 Phase II LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting USA | CAN 6
NCT03646461 Phase II Ibrutinib + Nivolumab Cetuximab + Ibrutinib Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC Recruiting USA 0
NCT03650764 Phase Ib/II Pembrolizumab + Ramucirumab Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03652233 Phase I Afatinib + Nivolumab Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Withdrawn 0
NCT03655444 Phase Ib/II Abemaciclib + Nivolumab Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy Terminated USA 0
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Recruiting USA 0
NCT03667482 Phase I Cabozantinib + Cetuximab Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Recruiting USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA 5
NCT03690986 Phase I Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer Recruiting USA 0
NCT03691714 Phase II Cetuximab + Durvalumab Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN 1
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03708224 Phase II Atezolizumab + Emactuzumab Atezolizumab Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma Recruiting USA 0
NCT03719690 Phase II Tipifarnib Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) Recruiting USA 17
NCT03723967 Phase II Carboplatin + Durvalumab + Paclitaxel FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE) Recruiting 1
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Active, not recruiting USA 0
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT03740100 Phase II PQR309 Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC) Completed USA 0
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting USA 0
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Active, not recruiting USA 0
NCT03769311 Phase II Cetuximab Cetuximab in Head and Neck Cancer Patients Recruiting USA 0
NCT03771820 Phase II Pembrolizumab NC-6004 + Pembrolizumab Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen Recruiting 8
NCT03789097 Phase Ib/II CDX-301 + Pembrolizumab + Poly ICLC Vaccination With Flt3L, Radiation, and Poly-ICLC Recruiting USA 0
NCT03795610 Phase II IPI-549 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03799744 Phase I Durvalumab + VCN-01 Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma Recruiting 1
NCT03803774 Phase I Birinapant Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) Recruiting USA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Recruiting USA 0
NCT03823131 Phase II Epacadostat + Pembrolizumab + Tavokinogene telseplasmid Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 0
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting USA 3
NCT03844763 Phase Ib/II Avelumab + Cyclophosphamide Targeting the Tumor Microenvironment in R/M SCCHN (CONFRONT) Recruiting 1
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting USA 0
NCT03854032 Phase II Nivolumab BMS-986205 + Nivolumab Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Recruiting USA 0
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Recruiting USA 5
NCT03878979 Phase II Nivolumab Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage Recruiting USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting USA | CAN 2
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting USA 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting USA 6
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA 4
NCT03937141 Phase II MIW815 + Pembrolizumab Previous Study | Return to List | Next Study Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer Active, not recruiting USA 0
NCT03938337 Phase II Abemaciclib + Pembrolizumab Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer Terminated USA 0
NCT03944915 Phase II Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) Recruiting USA 0
NCT03946358 Phase II Atezolizumab + UCPVax Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) Recruiting 1
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Recruiting USA 0
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Recruiting USA 2
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting USA 0
NCT03978689 Phase I CUE-101 A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03990233 Phase I Effi-DEM BI 754091 + Effi-DEM A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Recruiting 2
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT03993353 Phase II Pembrolizumab + Tadalafil Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting USA 0
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Recruiting USA 8
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting USA 5
NCT04034225 Phase Ib/II PAN-301-1 + Pembrolizumab Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN Terminated USA 0
NCT04052204 Phase II Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Terminated USA 3
NCT04058145 Phase II Pembrolizumab + Plerixafor AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Withdrawn USA 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting USA 0
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Recruiting USA | CAN 4
NCT04080804 Phase II Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Recruiting USA 0
NCT04091867 Phase I Cetuximab + sEphB4-HSA sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories Active, not recruiting USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04107103 Phase II Nivolumab + Pemetrexed Disodium Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus) Recruiting CAN 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Active, not recruiting USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04122625 Phase Ib/II Debio 1143 + Nivolumab Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Recruiting USA 2
NCT04128696 Phase III Pembrolizumab GSK3359609 + Pembrolizumab Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Active, not recruiting USA | CAN 24
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Recruiting USA | CAN 1
NCT04144517 Phase II ALKS 4230 + Pembrolizumab A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer Active, not recruiting USA 0
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04150900 Phase II Bavituximab + Pembrolizumab 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Recruiting USA 0
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04169074 Phase II Abemaciclib Abemaciclib + Nivolumab Modulation of the Tumor Microenvironment by Abemaciclib in Operable HPV-Negative Head and Neck Cancer (HNC) Recruiting USA 0
NCT04180215 Phase Ib/II HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers Recruiting USA 0
NCT04188951 Phase I Pembrolizumab HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer Recruiting USA 0
NCT04193293 Phase Ib/II Duvelisib + Pembrolizumab A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer Suspended USA 0
NCT04196283 Phase I ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-181 + ABBV-368 + IMO-2125 + Nab-paclitaxel A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting USA 5
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04220775 Phase Ib/II M7824 M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer Recruiting USA 0
NCT04220866 Phase II MK-1454 + Pembrolizumab Pembrolizumab Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Active, not recruiting USA 9
NCT04247282 Phase Ib/II M7824 ETBX-011 + ETBX-051 + ETBX-061 + M7824 ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + M7824 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection Suspended USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Withdrawn CAN 0
NCT04266730 Phase I PANDA-VAC + Pembrolizumab + Poly ICLC Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) Not yet recruiting USA 0
NCT04272333 Phase I Motolimod + Nivolumab Intratumoral Microdosing of Motolimod in HNSCC Recruiting USA 0
NCT04282109 Phase II Nivolumab + Paclitaxel Cetuximab + Paclitaxel Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX) Recruiting 1
NCT04290546 Phase I ALT-803 + CIML-NK cells + Ipilimumab ALT-803 + CIML-NK cells CIML NK Cell in Head & Neck Cancer Recruiting USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting USA 0
NCT04305795 Phase Ib/II ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors Recruiting USA 0
NCT04313504 Phase II Dostarlimab-gxly + Niraparib Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Recruiting USA 0
NCT04326257 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Recruiting USA 0
NCT04338399 Phase III Buparlisib + Paclitaxel Paclitaxel The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN) Recruiting USA 0
NCT04340258 Phase Ib/II Pembrolizumab Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC Recruiting USA 0
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04349267 Phase Ib/II BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors Recruiting USA | CAN 3
NCT04357873 Phase II Pembrolizumab + Vorinostat Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) Recruiting 1
NCT04369937 Phase II Cisplatin + ISA101b + Pembrolizumab HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04375384 Phase II Cetuximab Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy Recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA 3
NCT04414540 Phase II Metformin + Pembrolizumab Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients Recruiting USA 0
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Recruiting USA 3
NCT04428151 Phase II Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Recruiting USA | CAN 8
NCT04428333 Phase III Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA | CAN 18
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Recruiting USA 1
NCT04452214 Phase I Nidanilimab + Pembrolizumab A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04453046 Phase I Pembrolizumab Hemopurifier Plus Pembrolizumab in Head and Neck Cancer Recruiting USA 0
NCT04454489 Phase II Pembrolizumab Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Recruiting USA 0
NCT04459715 Phase III Cisplatin + Debio 1143 Cisplatin A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy Recruiting USA | CAN 18
NCT04465487 Phase I Cemiplimab + REGN6569 Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Recruiting USA 1
NCT04470024 Phase I DPV-001 + INCAGN01876 + Retifanlimab DPV-001 + Retifanlimab Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC Recruiting USA 0
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. Recruiting USA 1
NCT04474470 Phase Ib/II Cetuximab + NT219 NT219 A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Recruiting USA 0
NCT04477759 Phase I Atezolizumab Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) Recruiting USA 0
NCT04489888 FDA approved Carboplatin + Paclitaxel + Pembrolizumab A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Recruiting USA | CAN 3
NCT04502888 Phase I SL-172154 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Recruiting USA 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Recruiting USA | CAN 2
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Recruiting USA | CAN 12
NCT04533750 Phase I MSC2490484A Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting USA 0
NCT04534205 Phase II BNT113 + Pembrolizumab Pembrolizumab A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) Recruiting USA 3
NCT04555837 Phase Ib/II Alisertib + Pembrolizumab Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Recruiting USA 0
NCT04574583 Phase Ib/II FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Suspended USA 0
NCT04576091 Phase I BAY1895344 + Pembrolizumab Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Suspended USA 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Recruiting USA 2
NCT04590963 Phase III Cetuximab Cetuximab + Monalizumab Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) Recruiting USA | CAN 23
NCT04601402 Phase I Avelumab + GEN-001 GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Recruiting USA 0
NCT04616196 Phase Ib/II Cetuximab + NKTR-255 A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Recruiting USA 0
NCT04624113 Phase Ib/II Pembrolizumab + Tazemetostat Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Recruiting USA 0
NCT04633278 Phase II Pembrolizumab + QbG10 CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04634825 Phase II MGA271 + Retifanlimab MGA271 + MGD013 Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Recruiting USA 6
NCT04643379 Phase II Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Recruiting USA 0
NCT04665843 Phase II Atezolizumab + MTIG7192A Atezolizumab A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) Recruiting USA 12
NCT04671667 Phase II Cisplatin Pembrolizumab Carboplatin Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Recruiting USA | CAN 0
NCT04675294 Phase II ALX148 + Pembrolizumab Pembrolizumab ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03). Recruiting USA 2
NCT04675333 Phase II ALX148 + Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab ALX148 + Cisplatin + Fluorouracil + Pembrolizumab ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) Recruiting USA 2
NCT04681469 Phase II Dostarlimab-gxly + Niraparib Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (PRIME) Recruiting 1
NCT04685499 Phase II OBP-301 + Pembrolizumab Phase 2 Study of OBP-301 (Telomelysin) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease Recruiting USA 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Recruiting USA | CAN 0
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Recruiting USA 7
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04722523 Phase I Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Recruiting USA 0
NCT04747054 Phase III Pembrolizumab + Radiotherapy Pembrolizumab Study on the Efficacy of Radiotherapy Added to Pembrolizumab in Newly Diagnosed Metastatic Head and Neck Cancers (PembroMetaRT) Recruiting 1
NCT04752215 Phase I BI 754091 + BI 765049 BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker Recruiting USA 0
NCT04754321 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer Not yet recruiting USA 0
NCT04762225 Phase I RPTR-168 RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma Recruiting USA 0
NCT04777994 Phase I ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors Recruiting USA 2
NCT04811027 Phase II Eftilagimod alpha + Pembrolizumab Pembrolizumab Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) Recruiting USA 0
NCT04815720 Phase Ib/II Pembrolizumab + Pepinemab Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84) Recruiting USA 0
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Recruiting USA 0
NCT04831320 Phase II Nab-paclitaxel + Nivolumab Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor Recruiting USA 0
NCT04834349 Phase II NBTXR3 + Pembrolizumab Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Recruiting USA 0
NCT04847466 Phase II ALT-803 + PD-L1.t-haNK cells + Pembrolizumab Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer Not yet recruiting USA 0
NCT04848116 Phase II Cabiralizumab + Nivolumab BMS-986253 + Nivolumab Nivolumab Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2) Recruiting USA 0
NCT04854499 Phase II Carboplatin + Fluorouracil + Pembrolizumab Docetaxel + Hu5F9-G4 Cisplatin + Fluorouracil + Pembrolizumab Hu5F9-G4 + Pembrolizumab Carboplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab Cisplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma Recruiting USA 1
NCT04862455 Phase II NBTXR3 + Pembrolizumab NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer Recruiting USA 0
NCT04862650 Phase II Carboplatin + Cemiplimab + Paclitaxel Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Not yet recruiting USA 0
NCT04879849 Phase I Pembrolizumab + TAK-676 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Recruiting USA 0
NCT04936841 Phase II NKTR-214 + Pembrolizumab NKTR With Radiation for Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04938609 Phase II Pembrolizumab Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) Not yet recruiting USA 0
NCT04939480 Phase II Atezolizumab Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (PIONEER) Recruiting 1
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Not yet recruiting USA | CAN 0
NCT04966481 Phase III Cetuximab + Palbociclib Cetuximab Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor Not yet recruiting USA 0
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Suspended USA 0
NCT04999202 Phase I BAY2416964 + Pembrolizumab BAY2416964 A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults Recruiting USA 3
NCT05005403 Phase I ABBV-181 + ABBV-514 ABBV-514 + Pembrolizumab ABBV-514 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab Not yet recruiting USA 2
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05039801 Phase I IPN60090 IPN60090 + Pembrolizumab IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05057247 Phase II Docetaxel + Duvelisib Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Not yet recruiting USA 0